Melatonin is a pleiotropic hormone with several functions. It binds to specific receptors and to a number of cytosolic proteins, activating a vast array of signalling pathways. Its potential to protect the heart against ischaemia/reperfusion damage has attracted much attention, particularly in view of its possible clinical applications.
| INTRODUCTION
Despite the extensive progress in the knowledge and understanding of cardiovascular diseases concomitant with new pharmacological approaches and procedural interventions, it remains the leading cause of death globally. 1 It is generally accepted that, although early reperfusion is the most effective strategy to salvage endangered tissue, it also leads to generation of excessive amounts of free radicals and its associated harmful effects, which in turn hampers recovery. In view of this and also the failure of several drugs to translate successfully from the bench to bedside, there has been an active interest in the development of novel adjunctive therapeutic strategies to limit myocardial ischaemia/reperfusion injury (I/R). Amongst these, melatonin, a hormone secreted mainly by the pineal gland, has received much attention. It has been shown to protect against I/R injury in various organs, including the heart, 2,3 liver, 4 ,5 brain, 6 ,7 kidney, 8 intestine, 9 lung 10 and testes. 11 These convincing experimental data stressed the necessity of evaluating melatonin's effects in humans with cardiovascular disease. In fact, a recent editorial by Dominguez-Rodriquez et al 12 addressed the question as follows: "melatonin for cardioprotection in ST elevation myocardial infarction: are we ready for the challenge."
The current interest in melatonin as cardioprotective agent is also reflected in the number of recent extensive reviews on this topic. [13] [14] [15] Using isolated perfused hearts or cardiomyocytes as experimental models, melatonin (pretreatment or addition of melatonin directly to the perfusion or incubation medium) reduced infarct size after coronary artery ligation, 14, 16, 17 reduced the incidence of reperfusion arrhythmias 18 and counteracted the elevated release of cytochrome c resulting from increased susceptibility to Ca 2+ -induced mitochondrial permeability transition pore (MPTP) opening. 19, 20 Melatonin treatment has been shown to protect the heart against damage induced by chronic intermittent hypoxia, angiotensin II, 22 isoproterenol, 23 epinephrine 24 and doxorubicin. 25 In addition, it also protects against sepsis-induced myocardial injury 26, 27 and hypertrophy induced by aortic constriction. 28 However, this review will focus mainly on the signalling events associated with melatonin-induced cardioprotection during exposure of the heart to ischaemia followed by reperfusion, with special reference to a number of studies where myocardial infarction without reperfusion was discussed. Although it is appreciated that signalling will differ in hearts exposed to I/R, when compared to hearts exposed to prolonged ischaemia and infarct development, carefully controlled studies in this regard are still required. Attention will also be given to recent studies investigating the therapeutic potential of the hormone in patients with cardiovascular disease.
| MECHANISM(S) OF PROTECTION
Thus far, experimental evidence indicated that melatonin exerts its effects on the heart mainly via its free radical scavenging abilities and upregulation of antioxidant systems, as well as receptor-mediated signalling pathways. [29] [30] [31] [32] The relative importance of these systems in eliciting cardioprotection remains to be elucidated. Whether they are activated simultaneously or in sequence is difficult to determine experimentally. For example, the majority of studies in this regard made use of luzindole, a nonspecific melatonin receptor blocker, which completely abolishes melatonin's beneficial effects and complicates evaluation of the contribution of the other putative cardioprotective signalling pathways of melatonin. On the other hand, the contribution of free radical scavenging per se in melatonin-induced cardioprotection could be determined using analogues of melatonin.
| FREE RADICALS AND ANTIOXIDANT SYSTEMS
It is well-established that melatonin and its downstream metabolites are powerful direct free radical scavengers via receptor-independent mechanisms. [33] [34] [35] Within the cell, the free radical scavenging capacity of melatonin could be affected by its intracellular location. 36 Interestingly, it has been reported that the concentration of melatonin in the mitochondria is very much higher than those in other parts of the cell and suggested that the hormone should be classified as a mitochondriatargeted antioxidant. 35 As the major metabolites of melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N-acetyl-5-methoxykynuramine (AMK), also have free radical scavenging abilities, one molecule of melatonin can scavenge up to 10 reactive oxygen species (ROS) or reactive nitrogen species (RNS). 34 The physicochemical nature of the reaction between melatonin and free radicals has also been investigated. Several studies found that single electron and hydrogen atom transfer were important characteristics of the antioxidant activity of melatonin. [37] [38] [39] [40] Melatonin has been shown to directly scavenge the very toxic hydroxyl radical ( . OH) in vitro 41 and in vivo, 42 and radical adduct formation seems to be the major mechanism whereby melatonin detoxifies this particular radical. 43 Melatonin can also quench oxidative damage by virtue of its ability to bind heavy metals. It chelates both iron(III) and iron(II) which are the forms that participate in the Fenton reaction to generate the hydroxyl radical (for a review see ref 36 ). In addition, melatonin as well as its metabolites and chelate Cu(II) completely inhibit oxidative stress in a Cu(II)/ ascorbate mixture. 44 It was therefore proposed that melatonin, besides being the initial molecule in the free radical scavenging cascade, is also involved in a metal-chelating cascade.
Melatonin and its metabolites have been demonstrated to modulate the expression of genes involved in detoxification or generation of ROS/RNS (for reviews see refs 45, 46) . In this regard, Antolin et al 47 first demonstrated that melatonin enhanced the expression of genes involved in detoxifying ROS, including Cu-ZN superoxide dismutase (CuZnSOD) and manganese superoxide dismutase (MnSOD), in hamster Harderian gland. Melatonin-induced increased expression of CuZnSOD and glutathione peroxidase was also reported in vitro in neural cell lines as well as in vivo in neuronal tissues (for review see ref 29) . On the other hand, melatonin has been shown to inhibit nitric oxide synthase (NOS) activity in rat hypothalamus 48 and reduce expression of inducible NOS (iNOS) in liver and lung from lipopolysaccharide-challenged rats. 49 In summary, the melatonin-mediated changes in antioxidant enzyme gene expression are consistent with its ability to upregulate the activities of these enzymes. 46, 50, 51 It has been proposed that melatonin can also interact with calmodulin, which in turn inhibits downstream processes that lead to inactivation of the nuclear RORalpha melatonin receptor, 31 which may cause an increment in antioxidant enzyme activities. Apart from its free radical scavenging and antioxidative effects, melatonin has a remarkable array of means whereby it thwarts intracellular damage by activating specific signalling pathways downstream of the melatonin receptors. Although the minimal functional unit of the MT1 and MT2 receptors seems to be monomeric, it has been shown that these receptors form homo-and hetero-oligomers between themselves and other G-protein-coupled receptors. These dimers are functionally relevant and distinct from receptor monomers [for a review see ref 59] . It has been suggested that melatonin heterodimerization with other receptor types may generate additional signalling responses. 59 The significance of the MT1 and MT2 receptors in melatonin-induced cardioprotection was demonstrated convincingly by the finding that luzindole, a nonspecific melatonin receptor antagonist, 59 abolishes its cardioprotective actions. 60, 61 Importantly, the synthesis of melatonin, its concentration and receptor expression in vivo are affected by myocardial infarction: Sallinen et al 62 ) showed that induction of myocardial infarction in rats caused a significant increase in left ventricular and plasma melatonin levels within a day, followed by a marked increase in MT1 mRNA levels after 14 days, suggesting that melatonin could be an important endogenous protector against I/R injury.
| MT3 receptor
Another melatonin receptor, MT3, is designated a lowaffinity membrane receptor with a Kd in the nanomolar range. 63 Its role in the heart still needs to be clarified: should it be a membrane receptor, its signal transduction cascade and biological consequences are unknown. It is known that the MT3 melatonin binding site is an enzyme, quinone reductase (QR2), and it has been hypothesized that melatonin is a co-substrate of QR2, which, in turn, plays an important role in balancing generation of free radicals. 63 It has recently been suggested that this particular melatonin receptor may be involved in the cardioprotective actions of melatonin in rats in vivo and in vitro: inhibition of MT3 with prazosin abolished the infarct-sparing ability of melatonin and attenuated the effects of red wine. 61 It should, however, be kept in mind that prazosin is also an alpha-adrenergic receptor blocker. As stated above, very little is known about the downstream effects of this receptor or whether it would activate the same pathways as MT1 and MT2, especially with regard to its cardioprotective actions.
| RZR/RORalpha
Melatonin is also a ligand for a nuclear retinoid-related orphan receptor (RZR/RORalpha). These nuclear receptors belong to the RZR/ROR orphan receptor subfamily, which includes three subtypes (alpha, beta, gamma) 63, 64 ). These receptors, especially the RORalpha subtype, are circadian clock proteins involved in diurnal rhythm regulation. Melatonin has been shown to interact with these receptors, 63-67 which could mediate some of the biological effects of melatonin.
In an interesting recent study, He et al 68 reported that the nuclear melatonin receptor, RORalpha, was a novel endogenous defender against myocardial I/R injury. Using mice, they showed that RORalpha deficiency significantly increased infarct size, apoptosis, and aggravated cardiac dysfunction after I/R injury. Molecular analysis indicated that these detrimental effects of RORalpha deficiency could be attributed to the augmented activation of the endoplasmic reticulum (ER) stress-and mitochondria-mediated apoptotic pathways, autophagy dysfunction and oxidative/nitrative stress. They also observed that deficiency of the nuclear melatonin receptor RORalpha significantly reversed the melatonin-exerted cardioprotection against I/R injury and vice versa, overexpression of this receptor in cardiomyocytes renders them less vulnerable to I/R injury. 
| TNFR2 and TLR4 receptors
The tumour necrosis factor receptor 2 (TNFR2) as well as the Toll-like receptor 4 (TLR4) has also been implicated in the cardioprotective actions of melatonin ( Figure 2 
| Events downstream of melatonin receptor activation
Most of the effects of melatonin are linked to light or darkness, and much of the earlier work on melatonin action focused on its effects on adaptation of the photoreceptor located in the retina and the entrainment of circadian and seasonal rhythms by the light-dark cycle (see ref 71 for review).
As stated above, many of melatonin's effects are mediated by its high-affinity receptors located in the cell membrane which are coupled to heterotrimeric Gi proteins formed by alpha, beta and gamma subunits. Activation of the MT1 and MT2 receptors promotes dissociation of the G proteins into alpha and beta-gamma subunits which then interact with various effector molecules. 72, 73 Amongst others, the signalling pathways coupled to melatonin receptor activation have been studied in mammalian cell lines expressing recombinant MT1 and MT2 receptors. 35, 74 However, information regarding downstream events is still incomplete due to the large number of binding sites for melatonin as well as differences between responses in different organs and the fact that a systematic investigation of the sequence of events of a particular signalling pathway in a specific organ has not been done thus far. The MT1 receptor elicits multiple cellular responses through both pertussis toxin-sensitive and pertussis toxininsensitive pathways (see Figures 1 and 2 ). For example, activation of the MT-and cAMP-responsive element-binding protein (CREB) phosphorylation inhibits forskolin-stimulated cAMP formation and protein kinase A (PKA) activity. 73, 75, 76 It also stimulates c-Jun N-terminal kinase (JNK) activity via both pertussis toxin-sensitive and pertussis toxin-insensitive proteins. 77 Other actions of this receptor include increased phosphorylation of mitogen-activated protein kinase kinases 1 and 2 (MEK1 and 2), extracellular signal-regulated kinase 1 and 2 (ERK 1 and 2) 77, 78 and increased phosphoinositide hydrolysis via phospholipase C beta activation. 79 Downstream activation of protein kinase C (PKC) appears to be a critical step in melatonin action via both the MT1 and MT2 receptors. 65 The potent anti-adrenergic effects of melatonin have also been demonstrated in the myocardium: Genade et al 80 showed that melatonin significantly counteracted the powerful beta-adrenergic stimulation by forskolin and isoproterenol in a receptor-dependent manner in normoxic perfused rat hearts. Nitric oxide (NO), guanylyl cyclase, as well as PKC were involved in these actions since the inhibitors l-nitro-l-arginine methyl ester (L-NAME), 1H- [1, 2, 4] oxadiazolol- [4, 3] quinoxaline-1one (ODQ) and bisindolylmaleimide, respectively, could counteract these actions. These anti-adrenergic actions are receptor-dependent and can be abolished by melatonin receptor blockade with luzindole. Since melatonin has been shown to activate PKC, the anti-adrenergic effects of melatonin could be due to inhibitory cross-talk between PKC and protein kinase A (PKA). 81, 82 Interestingly, much of our current knowledge regarding the effects of melatonin on intracellular signalling in the myocardium, emanated from studies done in the quest for identifying the mechanism of melatonin-induced cardioprotection. As far as we are aware, relatively few studies have been done on the effects of melatonin signalling per se in the heart under baseline conditions. In this regard, a previous study from our laboratory showed that administration of melatonin (4 mg/kg/d) for 3-6 weeks upregulated baseline cytosolic protein kinase B (PKB) and STAT-3 activation. 83 It has also been shown that melatonin activates both STAT-3 and JAK2 in control perfused hearts 61, 69, 84 as well as in neonatal cardiomyocytes. 84 In summary, these data indicated that melatonin treatment upregulated activation of PKB, STAT-3 and JAK2 in the heart under control baseline conditions. As far as we are aware, ERK activation has not been studied in the myocardium in this regard.
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| RISK PATHWAY
As stated above, much of our knowledge, regarding events downstream of melatonin receptor binding to its ligand, stems from our interest in the ability of the hormone to protect the heart against the development of I/R injury ( Figure 1 ). Thus, information was obtained in both in vitro and in vivo models of myocardial I/R injury, where signalling events could be studied particularly during the reperfusion period of hearts subjected to ischaemia to allow correlation of infarct size with intracellular events during early reperfusion. In these studies, melatonin was added either to the perfusate or the animals were pretreated with melatonin. In our own laboratory, it was found that the reduction in infarct size induced by either long-term (16-20 weeks) or short-term (3-6 weeks) melatonin treatment was associated with a significant activation of the prosurvival kinases, PKB and ERK (the socalled RISK pathway), and inactivation of pro-apoptotic mitogen-activated protein kinase p38 (p38MAPK) during reperfusion. For the first time, melatonin-induced phosphorylation and thus inactivation of glycogen synthase kinase-3beta (GSK-3beta) during reperfusion were also reported, probably resulting from the upstream activation of PKB and ERK. 16, 83 A direct link between the melatonin receptor and activation of the PKB/ERK pathway during reperfusion was shown in our laboratory: co-administration of luzindole (1 mg/kg/d) and melatonin (5 mg/kg/d) for 1 week abolished both the melatonin-induced reduction in infarct size and activation of the RISK pathway (Lochner & Genade, unpublished data).
The significance of activation of the RISK pathway during reperfusion in cardioprotection has been studied particularly in the setting of ischaemic preconditioning. The requirement for PKB activation in cardioprotection was first demonstrated by Tong et al 85 who reported that its inhibition during a preconditioning stimulus abolished protection. These results were subsequently confirmed by Salie et al. 86 The role of ERK activation during preconditioning was less certain, and conflicting data were reported. [87] [88] [89] However, activation of the RISK pathway at the time of reperfusion in ischaemic or pharmacological preconditioning as well as postconditioning has been confirmed to be associated with cardioprotection in many experimental models. It has also been shown that phosphorylation of both PKB and ERK is biphasic, the first phase occurring during the preconditioning protocol and the second phase during early reperfusion. 90 The significance of PKB and ERK activation during reperfusion in melatonin-treated hearts was further studied by blockade of PKB or ERK by A6730 (2.5 μmol/L) or PD98059 (10 μmol/L), respectively: both blockers completely abolished the significant melatonin-induced reduction in infarct size (Lochner & Genade, unpublished observations 92 and PKC. 90 Phosphorylation and inactivation of other apoptotic effectors such as Bcl-2-associated death promotor (BAD), GSK-3beta, B-cell lymphoma-associated X (Bax) and caspases have also been reported. 93 It is now generally accepted that activation of the RISK pathway confers cardioprotection via inhibition of the opening of the MPTP. 93 A number of studies demonstrated a role for melatonin in the modulation of MPTP opening. 19, 94, 95 For example, Andrabi et al 95 reported that melatonin directly inhibits the MPTP and Petrosillo et al 19 showed that melatonin, by preventing endogenous cardiolipin peroxidation, inhibits MPTP opening. They also showed that release of cytochrome c from mitochondria, associated with opening of the pore induced by oxidative stress, could be almost completely inhibited by melatonin.
| SAFE PATHWAY
Activation of the SAFE or JAK/STAT pathway should also be considered an important signalling pathway in melatonininduced cardioprotection ( Figure 1 ). Lecour et al 96 previously demonstrated that tumour necrosis factor alpha (TNFalpha) protects the heart against I/R damage via phosphorylation of STAT-3 during reperfusion and that its inhibition by the JAK/STAT inhibitor AG490 abolishes protection.
Using an isolated perfused heart as model, these workers subsequently showed that administration of a very low dose of melatonin (75 ng/mL (32 nmol/L)) for 15 min before the onset of ischaemia increased STAT-3 phosphorylation prior to ischaemia and concluded that the hormone protects the heart via activation of the SAFE prosurvival pathway. 17, 96 Melatonin treatment failed to protect the heart when administered to STAT3-knockout mice, confirming the significance of STAT-3 activation in melatonin-induced cardioprotection. Yang et al 84 subsequently confirmed the involvement of the JAK2/STAT-3 pathway in melatonin-induced protection. These workers investigated the effect of melatonin using isolated perfused rat hearts as well as neonatal cardiomyocytes and showed that it improved postischaemic function, reduced infarct size, apoptotic index, and lactate dehydrogenase release as well as downregulated the pro-apoptotic protein Bax and attenuated mitochondrial oxidative damage. These beneficial effects could be blocked by either AG490 or JAK2 siRNA.
The link between the JAK/STAT pathway and the melatonin receptor was further explored, and it was shown that luzindole, the nonselective melatonin receptor antagonist, attenuates the promotion of astroglial cell survival and STAT-3 phosphorylation by melatonin. 97 Downstream effectors of the SAFE pathway include a number of proteins involved in cell survival, for example B-cell lymphoma 2 (BcL-2), B-cell lymphoma-extra large (BcL-xL), myeloid cell leukaemia (Mcl-1), fatty acid synthetase (FAS), cyclin D1 and p21. [98] [99] [100] STAT-3 also phosphorylates and inactivates GSK-3beta. 101 As in the case of the RISK pathway, the prosurvival mechanism of STAT-3 was suggested to target inhibition of the MPTP. [102] [103] [104] [105] Further evidence of a link between activation of the SAFE pathway and inhibition of MPTP opening was the finding that high-density lipoproteins protect against ischaemia/reperfusion injury also via inhibition of MPTP opening and activation of the SAFE pathway.
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Lecour and co-workers reported that activation of the SAFE pathway acts independently from the activation of the RISK pathway, which suggested that activation of both pathways at the time of reperfusion is not always required for cardioprotection. For example, it has been shown that cardioprotection could be obtained in the presence of RISK path blockade. 96, 105 It is, however, possible that interaction between the two pathways may occur via cross-talk between PI3K/PKB and JAK/STAT-3. For example, it has been shown that opioid-induced cardioprotection is associated with activation of both these pathways and, more importantly, that STAT-3 phosphorylation was dependent on phosphoinositide-3-kinase (PI3K) activation. 101 Further evidence of cross-talk between these two pathways was the finding that PKB phosphorylation was reduced in the presence of the JAK/STAT-3 inhibitor (AG490), while STAT-3 phosphorylation was reduced in the presence of wortmannin, a PI3K inhibitor. 108 Whether these interactions also occur with melatonin treatment or whether the one pathway exceeds the other remains to be established.
| SIRTUINS (SILENT INFORMATION REGULATOR)
The sirtuins, particularly sirtuin-1 (Sirt1) and sirtuin-3 (Sirt3), have recently been suggested as downstream role players in the cardioprotective actions of melatonin ( Figure 2 ). These are highly conserved nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases, expressed in the heart. Mitochondrial sirtuins include Sirt3, Sirt4 and Sirt5. Amongst them, Sirt3 possesses robust deacetylizing activity and controls the acetylation status of almost 80%-100% of the mitochondrial proteins. 109 Both Sirt1 and 3 have multiple functions in the heart. Sirt1 can modulate fatty acid oxidation, cardiac hypertrophy, apoptosis, oxidative stress and autophagy through deacetylation of NF-κB, PKB, Forkhead box class O (FoxO), p53, peroxisome proliferator-activated receptor-alpha (PPAR-alpha), thioredoxin-1 (Trx1), Bcl-xL. 110 It is known that both Sirt1 111, 112 and Sirt3 113,114 signalling protect against I/R injury and that Sirt1 expression is reduced by exposure of the heart to I/R. Involvement of Sirt1 in I/R injury was initially indicated by the observation that Sirt1-deficient mice exhibit increased injury in response to I/R while cardiac damage was reduced in Sirt1 transgenic mice. 111 In addition, upregulation of Sirt1 111,112 signalling has been shown to protect against I/R injury. Hsu et al 111 suggested that Sirt1 protects against I/R injury by upregulating antioxidants and downregulating pro-apoptotic molecules by activation of FOXO1. The role of Sirt1 in melatonin-induced cardioprotection was further investigated by Yu et al, 115 using a model of in vivo coronary artery ligation after 7 days of melatonin administration (10 mg/kg/d) to rats, with or without co-administration of luzindole and EX527, a Sirt1 inhibitor. The results showed the expected melatonin-induced reduction in I/R damage, associated with increased Sirt1 and BcL2 expression and a reduction in BAX and caspase 3 cleavage. These workers also showed that Sirt1 inhibition by EX527 abolished the marked effects of melatonin on oxidative stress, for example the reduction in I/R-induced superoxide generation, gp91phox expression and malondialdehyde (MDA) levels and the increase in superoxide dismutase (SOD) levels. These protective effects were also blocked by luzindole which indicate a role for the melatonin receptor in Sirt1 activation by melatonin. The results furthermore suggested that melatonin-induced cardioprotection involved activation of Sirt1 which may, via decreased acetylation of FOXO1, promote anti-apoptotic signalling in the heart. Although luzindole indicated melatonin receptor involvement, it still remains to be established which of these receptors are involved in the upregulation of Sirt1. As stated above, Sirt3 also protects against oxidative stress-related diseases, including myocardial I/R injury. 113, 114, 116 This sirtuin regulates mitochondrial permeability transition pore (mPTP) opening, apoptosis, and cell survival, mainly through deacetylation of mitochondrial proteins, including cyclophilin D (CypD), Ku70, and complex I, independently of transcription. Sirt3 moreover deacetylates FOXO3, leading to transcriptional upregulation of MnSOD and catalase and inhibition of cardiac hypertrophy. 117, 118 In addition to the above, Zhai et al 117 reduction in the acetylation of SOD2 which was largely abolished by 3-TYP. In addition, Sirt3-targeted siRNA abolished the beneficial effects of melatonin in H9c2 cells subjected to simulated I/R, lending support to their suggestion that melatonin ameliorates I/R-induced oxidative stress by activating the Sirt3 pathway. It was also found that melatonin reduces the translocation of Bax to the mitochondria via activation of Sirt3, indicating that the protective effect of the hormone against I/R induced apoptosis is mediated, at least in part, by Sirt3 signalling. Thus, existing evidence suggests that both Sirt1 and Sirt3 could act as essential downstream molecules mediating melatonin actions. Experimental evidence shows the existence of a tight relationship between these two sirtuins. Zhai et al 117 reported a significant reduction in both Sirt1
and Sirt3 after exposure to I/R, with melatonin simultaneously upregulating their expression levels. They also found that EX527, a selective Sirt1 inhibitor, as well as Sirt1 siRNA, diminished the melatonin-induced increase in Sirt3 expression and decrease in the acetylated SOD2/SOD2 ratio following I/R. Interestingly, the Sirt3 inhibitor and siRNA had little effect on Sirt1 expression, suggesting that Sirt1 may be an upstream molecule that affects the expression of Sirt3 in melatonin cardioprotection. Sirt1 is also an important upstream molecule of Nrf2, 119 another role player in melatonin's antioxidative effects, 120 which can bind to Sirt3 promoter to regulate its expression. 121 Zhai et al 117 did not investigate the role of the melatonin receptor in its effects on Sirt3, although it is expected to be receptor-dependent, if it is localized downstream of Sirt1 signalling pathways, the activation of which is melatonin receptor dependent. 115 The possibility that melatonin might regulate Sirt3 expression in a Sirt1-Nrf2-dependent manner needs to be further explored (see section on NRF2). Additionally, Sirt3 has been found to serve as a downstream target of AMP-kinase (AMPK)-activated peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) which enhances mitochondrial biogenesis and the deacetylation of mitochondrial antioxidative enzymes.
122,123 PGC-1alpha has been reported as a critical downstream molecule of AMPK, [124] [125] [126] and inhibition of AMPK significantly downregulated PGC-1alpha and Sirt3 signalling. AMPK has been shown to play a pivotal role in melatonin's protective actions: using compound C (a specific AMPK signalling blocker), the beneficial actions of melatonin on the outcome of I/R injury (infarct size reduction, inhibition of apoptosis) could be abolished. 127 It has been shown in murine retina cells that PGC1alpha was the target gene of melatonin, an action in which the melatonin receptors participated. 128 However, as stated above, the role of the melatonin receptor in Sirt3 signalling in myocardial I/R injury still needs to be evaluated. Furthermore, the possibility of links between the signalling pathways of the sirtuins and the other pathways known to be activated by melatonin (RISK, SAFE) and whether they are activated independently from each other remain to be unravelled.
| MAMMALIAN STE20-LIKE KINASE (MST1)
In addition to studies on the effects of melatonin on I/R injury, the effects of the hormone were also recently evaluated in the context of remodelling after myocardial infarction (in vivo coronary artery ligation for 4 weeks, without reperfusion) (Figure 2 ). Using this model, Hu et al 129 showed
that melatonin significantly mitigated adverse left ventricular remodelling, associated with enhanced autophagic flux, reduced apoptosis and improved mitochondrial function. Furthermore, in this experimental setting melatonin significantly inhibited Mst1 phosphorylation, while promoting Sirt1 expression after myocardial infarction. Mst1, the chief component of the mammalian Hippo pathway, well-known for its pro-apoptotic effects, directly inhibits the deacetylation activity of Sirt1 by phosphorylation. The role of Mst1 was further investigated using Mst1-knockout and transgenic mice which showed that the absence of Mst1 abolished the beneficial effects of melatonin after myocardial infarction, suggesting that Mst1/Sirt1 signalling may serve as a downstream target of melatonin. 129 Hu et al 129 also reported that cardiac dysfunction and left ventricular remodelling were not reversed by melatonin treatment in Sirt1-knockout mice. These observations led these workers to propose that Mst1 may serve as a crucial molecular target of melatonin to alleviate postinfarction remodelling after MI. Unfortunately, in their study the interactions between Mst1/Sirt1 and the RISK and SAFE pathways were not investigated. As far as we are aware, the role of Mst1 in the setting of I/R injury has not yet been investigated. Mst1 also plays an important role in protein quality control and cardiac remodelling in diabetic cardiomyopathy. A recent study by Zhang et al 130 showed that the beneficial effects of melatonin on diabetic cardiomyopathy were due to inhibition of Mst1 phosphorylation and increased Sirt3 expression, which, in turn, were associated with an increase in autophagy and reduction in apoptosis and mitochondrial dysfunction. Thus according to existing literature, melatonin exerts its effects in remodelling via Mst1, Sirt1 as well as Sirt3.
| NOTCH PATHWAY
The Notch pathway is an evolutionary conserved fundamental pathway that regulates cell destination during development as well as throughout life in self-renewing tissues (Figure 2) . 131, 132 To date, four Notch receptors (Notch 1-4) and two types of Notch ligands (Jagged and Delta) have been discovered in mammals. 133 Downstream genes of Notch signalling include Hairy and enhancer of split 1 (Hes 1) and the Hairy-related transcription (HRT) factor family. Hes 1, in turn, has been shown to negatively regulate the enzyme phosphatase and tensin homolog deleted on chromosome 10 (PTEN), the inhibitor of PI3K/PKB signalling, in thymocytes and T-cell lymphoblastic leukaemia (T-ALL) cells.
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The Notch pathway has been shown to be involved in cardioprotection: a recent study revealed that activation of this pathway protected against I/R damage by reducing cardiomyocyte apoptosis. 131 Yu et al 136 The role of the Notch 1 pathway in melatonin signalling was further investigated by Pei et al. 137 It was demonstrated that the anti-apoptotic effects of Notch 1 in differentiated cells are mediated by the mitochondrial fusion-associated protein (Mfn2), an important role player in mitophagy. 138 In a study on the effects of melatonin on myocardial infarction remodelling, these workers used coronary artery ligation in vivo (without reperfusion) combined with intramyocardial injection with siRNA against Notch 1 or the ligand Jagged 1 peptide. Their results showed that ablation of Notch 1 or Mfn2 aggravated postinfarction injury, while Jagged 1 attenuated these harmful effects. As observed by Yu et al, 136 melatonin increased expression of Notch 1, which was associated with a reduction in fibrosis, superoxide generation and apoptosis. Very importantly, melatonin did not attenuate postinfarct injury in mice deficient in either Notch 1 or Mfn2. It was concluded from this study that Mfn2 plays an indispensable role in Notch 1-induced protection. These effects were also melatonin receptor dependent, as indicated by reversal of its effects by luzindole pretreatment. Activation of PKB via Notch 1 signalling and PTEN inhibition is melatonin receptor dependent as indicated by the effects of luzindole treatment, suggesting that melatonininduced activation of the RISK pathway may depend, in part, on the Notch 1 pathway. 136 Cross-talk between PKB, ERK1/2 and Notch signalling during myocardial reperfusion has been reported previously in the case of berberine-induced cardioprotection.
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| NRF2
Nrf2 is a transcription factor which is responsible for the regulation and management of many antioxidant response genes after binding to the DNA antioxidant response element (ARE; Figure 2 ). 141 Several recent studies linked the beneficial effects of melatonin in I/R to Nrf2 pathway activation. 142, 143 After binding to ARE, Nrf2 transactivates the expression of a group of cytoprotective enzymes including haem-oxygenase-1 (HO-1), NADPH, quinone oxidoreductase-1 and GSH-Stransferase alpha-1. 144 The Nrf2-ARE pathway is considered a major protective pathway and may play an important role in I/R injury. Melatonin is a ligand for the nuclear RZR/ RORalpha receptor and binds to transcription factors in the nucleus. Whether the Nrf2 pathway is linked to the nuclear melatonin receptor or other receptors and other signalling pathways remains to be elucidated.
| ROLE OF THE MITOCHONDRION IN MELATONIN-INDUCED CARDIOPROTECTION
The mitochondrion, responsible for generating ATP for the contractile activity of the heart, appears to be the crucial target for melatonin to exert its protection against I/R injury, and according to Reiter et al, 145 the hormone meets the criteria as a mitochondria-targeted antioxidant (Figures 1-3) . One of the earliest studies to link the beneficial effects of melatonin to an improvement in mitochondrial function was carried out by Petrosillo et al 146 : exposure of the heart to I/R showed significant changes in mitochondrial oxygen consumption, complex I and complex III activity, H2O2 production as well as the degree of lipid peroxidation, cardiolipin content and cardiolipin oxidation. Melatonin treatment attenuated these alterations which were attributed to the preservation of the content and integrity of cardiolipin molecules. As stated previously, these beneficial actions of melatonin coincided with prevention of mitochondrial permeability transition and a reduction in cytochrome C release. 19 Apart from its effects on the outcome of I/R, recent evidence revealed an intricate relationship between melatonin and its actions and the mitochondrion per se which may clarify some of its actions. Interestingly, measurement of the subcellular distribution of melatonin showed that the concentration of the indole in the mitochondria greatly exceeds that in the blood. 145 Although passive diffusion across membranes was generally accepted to explain the presence of melatonin in organelles, it has now been shown that the uptake of melatonin by the mitochondria is mediated by the oligopeptide transporters GLUT transporter/solute carrier family 2A (GLUT/SLC2A10) and PEPT1/2 (SLC15A1/2). 147, 148 Furthermore, the localization of these two transport systems
in the mitochondria strongly suggests the participation of both in mitochondrial transport of melatonin. 149 Furthermore, contrary to MT2, substantial quantities of MT1 were found to be present in the mitochondrial fraction of brain tissue.
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A recent study in mouse brains 151 ( Figure 3) showed that melatonin was synthesized in the mitochondrial matrix due to the presence of two key melatonin biosynthetic enzymes, namely arylalkylamine N-acetyltransferase (AANAT) and acetylserotonin O-methyltransferase (ASMT). Melatonin is bound by the high-affinity MT1 receptor located in the outer mitochondrial membrane, with its ligand binding domain facing the cytosol and its signal transduction apparatus located in the intermembrane space. It was also demonstrated that melatonin activates the mitochondrial MT1/Gαi protein signal system, blocks adenylate cyclase activity and inhibits stress-induced release of cytochrome C. 151 Whether the same holds true for heart muscle mitochondria remains to be established. It is now generally accepted that melatonin exerts its beneficial effects via the mitochondrial permeability transition pore. GSK-3beta received attention as a possible regulator of MPTP opening, as it is a common target of multiple signalling pathways, [152] [153] [154] including the RISK and SAFE pathways that lead to cardioprotection. Inhibitory phosphorylation of GSK-3beta at Ser9 has been shown to elevate the threshold for opening of the pore. 155 Although GSK-3beta predominantly resides in the cytosol, I/R significantly increased its levels in the mitochondria, which was achieved by direct interaction of the enzyme and the MPTP subunit proteins, 156 presumably by multiple mechanisms. Interestingly, thus far only one study reported increased phosphorylation of GSK3beta during reperfusion of hearts from rats pretreated for 3-6 weeks with melatonin. 83 The beneficial effects of melatonin were also attributed to activation of the prosurvival SAFE pathway, as discussed above. STAT-3, a transcription factor, has been shown to be located in the matrix of both subsarcolemmal and intermyofibrillar mitochondria. 154 Stat-3 is encoded in the nucleus and has to be imported into the mitochondria, a process suggested to occur via a TOM20-dependent pathway. 102 Activation of STAT-3 has been shown to attenuate opening of the mitochondrial permeability transition pore. 157, 158 Mitochondrial connexin 43, the increase of which is associated with attenuated opening of the MPTP, has been suggested to be a downstream effector of the SAFE pathway. 106 The stimulating effects of melatonin on STAT-3 phosphorylation have been shown to occur in the nucleus, 61, 69 as well as in the mitochondria. 69 In addition, STAT-3, a transcription factor of the manganese superoxide dismutase (MnSOD) gene, co-localizes and interacts with this protein to increase its antioxidant activity, which is so important in the mitochondrial antioxidant defence. 159, 160 The translocases in the outer mitochondrial membrane (TOM) complex are the entry gate for the majority of precursor proteins that are imported into the mitochondria and have been suggested to be involved in mitochondrial biogenesis and bioenergetics to meet metabolic demands under stress. TOM70 has been shown to be essential for importing PTEN-induced kinase 1 (Pink 1) into mitochondria, reducing myocardial vulnerability to ischaemic injury. 161 TOM70
F I G U R E 3
Proposed role of melatonin in mitochondria (based on information obtained in neuronal mitochondria 151 ). Melatonin synthesized in the mitochondrial matrix binds to the high-affinity MT1 receptor in the outer mitochondrial membrane and inhibits, via the protein Galphai, stress-induced activation of adenylate cyclase and release of cytochrome C 
MPTP
was also reported to suppress oxidative stress in myocardial hypertrophy. 162 In view of the fact that mitochondria, which provide more than 95% of the energy required for myocardial contraction, are also the major source of ROS in response to ischaemia, Pei et al 163 investigated the role of TOM70 in the ischaemic myocardium. Permanent coronary artery ligation in mice in vivo (without reperfusion) and neonatal murine cardiomyocytes in culture were used as models. Their results show that myocardial infarction caused a significant downregulation of TOM70 which was associated with aggravation of myocardial injury, increased mitochondrial fragmentation and ROS overload. Upregulation of TOM70 using lentivirus vectors carrying TOM70a sequences into the left ventricles of mice alleviated myocardial injury and improved function. Melatonin pretreatment of the mice (10 mg/kg/d) caused increased expression of PGC1alpha and attenuated myocardial injury in control, but not in TOM70-deficient mice. These actions could be abolished by luzindole, indicating melatonin receptor dependence of TOM70 effects. However, although the links between the melatonin receptor, PGC1alpha and TOM70 need to be further investigated, these observations provided evidence that TOM70 and its ability to regulate oxidative stress were critical to the observed beneficial effects of melatonin. Finally Sirt3, located in the mitochondria, is an important signalling molecule downstream of melatonin. However, in view of its tight relationship with cytosolic Sirt1, their respective roles in melatonin-induced cardioprotection were discussed together in the section on "Sirtuins."
| ANTI-INFLAMMATORY EFFECTS OF MELATONIN
It is well-established that the cellular injury induced by acute myocardial ischaemia initiates an acute pro-inflammatory response through the concerted action of several processes which, in turn, results in the release of a variety of proinflammatory mediators, such as cytokines, for example, interleukin-1beta (IL1beta), which are autocrine contributors to cardiac dysfunction [for a review see ref 164] . IL1beta is of particular importance as it can affect the innate immune system, mainly via activation of TLR4. Similarly, TNFalpha produced during I/R is an autocrine contributor to myocardial dysfunction and cardiomyocyte death. 165 It is also wellestablished that I/R activates myocardial p38 MAPK and nuclear factor kappa B (NF-kB) which leads to TNFalpha production. The cardiac effects of TNFalpha are bidirectional, including both negative inotropic and cardioprotective effects. 166 Recent studies suggest that this dual role of TNFalpha is dependent on which of its receptors are activated 167, 168 : TNFR1 (p55), which mediates adverse cardiac remodelling and TNFR2 (p75), whose pathways counter cardiac injury. Low doses of TNFalpha can protect against apoptosis in the setting of I/R injury. 96 A recent study using neonatal mouse cardiomyocytes demonstrated that TNFR2 activation increases p300/STAT-3/RelA/OPA1 signalling, enhances mitochondrial fusion, promotes respiratory activity and increases ATP levels, 169 and it was concluded that activation of this receptor protects cardiac myocytes against stress by upregulating optic atrophy 1 (OPA1) expression. In view of its effects on the SAFE pathway, it is possible that melatonin may also activate this particular pathway. However, as far as we are aware, such a study has not been done. The immunomodulatory capacity of melatonin, both in vivo and in vitro, has been verified by numerous previous studies [for reviews see refs [170] [171] [172] . For example, melatonin inhibits the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase as well as other mediators of the inflammatory process such as cytokines, chemokines and adhesion molecules. It has been shown to reduce NF-kB binding to DNA, probably by preventing its translocation to the nucleus, 173, 174 thereby curtailing the production of cytokines.
Despite the convincing laboratory evidence for melatonin's anti-inflammatory actions as discussed above, relatively little is known about its effects on the inflammatory response of the heart per se during I/R injury. In addition, extrapolation to the in vivo situation still needs to be further investigated.
A recent study showed a dose-dependent beneficial effect of melatonin pretreatment in 30 patients undergoing elective coronary artery bypass graft (CABG) namely a reduction in plasma cardiac troponin-1, IL1beta, iNOS and caspase levels. 175 However, Halladin et al 176 failed to demonstrate a reduction in oxidative/inflammatory markers by melatonin in an in vivo closed-chest porcine model of acute myocardial infarction. These workers are currently re-investigating their in vivo approach. 177 
| MELATONIN SIGNALLING IN CARDIAC MICROVASCULATURE
Microvascular ischaemia/reperfusion injury following percutaneous coronary intervention is caused by endothelial cell apoptosis, swelling, microvascular spasms and capillary obstruction, which reduce the effectiveness of reperfusion therapy and could compromise the clinical benefits of patients with acute myocardial infarction. 178 Melatonin has been shown to protect the microcirculation by maintaining the endothelial barrier function, 179 preserving endothelial permeability, 180 reducing cellular excessive oxidative stress 181 and alleviating endothelium-dependent NO overproduction. 182 Mitochondrial fission and mitophagy are important role players in the regulation of cell death, but it is unclear | LOCHNER Et aL.
whether these two processes are the triggers of cardiac microvascular I/R injury and cardiac microcirculation endothelial cell (CMEC) death and if so, whether melatonin could regulate these two processes. Melatonin is a known trigger of the AMPK pathway, 183 and recent studies 184 have shown that activation of AMPK could repress mitochondrial fission via inactivation of dynamin-related protein 1 (Drp1); however, whether melatonin protects cardiac microvasculature by modulation of mitochondrial fission and mitophagy, via activation of AMPK, was still unknown. Using in vivo coronary artery ligation in AMPKalpha−/− mice (AMPKalpha is the major isoform in endothelial cells), Zhou et al 185 showed that the beneficial effects of melatonin on the microvasculature were abolished and that I/R injury caused cardiac microcirculation endothelial cell death via excessive mitophagy. In vitro I/R activated Drp1-dependent mitochondrial fission, leading to opening of the mitochondrial permeability transition pore, upregulation of mitochondrial PINKI/Parkin and ultimately cell death. These reactions were suppressed by melatonin in an AMPKalpha-dependent manner. Zhou et al 185 also observed that melatonin improved CMEC survival via AMPKalpha, which is associated with less mitochondrial fission as evidenced by pDrp1 S616 downregulation and p-Drp1 S37 upregulation. This suppression of fission alleviates hexokinase 2 (HK2) dissociation from the mitochondria via inhibition of voltage-dependent anion channel 1 (VDAC1) oligomerization, blocking MPTP opening, ultimately promoting CMEC survival. As far as we are aware, this is the first study to show that melatonin also protects the cardiac microvasculature by inhibition of mitochondrial fission-VDAC-HK2-MPTPmitophagy via activation of AMPKalpha. Whether these processes also occur in the cardiomyocyte subjected to I/R damage remains to be further evaluated. Activation of AMPK upon exposure to stress is well-established, but little information is available regarding the effects of melatonin on mitophagy under these circumstances. Similarly, to our knowledge, little direct information is available regarding the role of the mitochondrial fission-VDAC-HK2-MPTP pathway in the cardiomyocyte. A shortcoming of the study of Zhou et al 185 is the use of global AMPKalpha-knockout mice for a study on isolated CMEC. Endothelial cell-specific AMPKalpha deletion could be an useful approach to determine the contribution of endothelial cell AMPKalpha to microvascular I/R injury. In a follow-up study, Zhou et al 186 investigated the role of platelet activation in microvascular damage induced by I/R injury. It is known that the fundamental factor in microvascular destruction is largely platelet microthrombosis which blocks the microvasculature. Using platelets isolated from patients with acute myocardial infarction undergoing coronary artery bypass grafting (CABG) as well as mice subjected to I/R injury, it was shown that peroxisome proliferator-activated receptor gamma (PPARgamma) was downregulated, which was associated with FUN14 domain containing 1 (FUNDC1) dephosphorylation, mitophagy activation, leading to enhanced mitochondrial function and increased ATP production. The improved mitochondrial function strongly contributed to platelet aggregation, formation of microthromboses, eventually resulting in myocardial dysfunction. Melatonin significantly suppressed platelet activation via restoration of the PPARgamma content in platelets, which subsequently blocked FUNDC1-induced mitophagy, mitochondrial energy production and reduced I/R injury. These results suggested that manipulation of the PPARgamma/FUNDC1/mitophagy pathway could be a novel approach to reduce I/R injury.
| MELATONIN SIGNALLING
IN PATHOPHYSIOLOGICAL CONDITIONS
Mitochondrial dysfunction is known to be an important contributor to the poor prognosis in the setting of myocardial I/R damage in diabetes. In view of its antioxidative actions and increasing the efficacy of the electron transport chain, the effects of melatonin on the heart in diabetes have recently attracted attention of researchers. Thus, the effects of melatonin treatment were evaluated on the metabolic profile of prediabetic rats and also rats with type 1 or type 2 diabetes. Nduhirabandi et al 16, 83 reported that hyperphagia-induced obese rats developed insulin resistance (but not diabetes) within a period of 16 weeks. Concomitant, long-term as well as short-term melatonin (4 mg/kg/d) treatment counteracted the harmful effects of obesity: it reduced body weight gain, lowered visceral adiposity, reduced serum insulin and HOMA-IR levels, while improving functional recovery after exposure of the heart to I/R. These beneficial effects of melatonin were associated with activation of STAT3, PKB, ERK1/2 and inactivation of GSK3-beta and p38MAPK during reperfusion after global ischaemia. Melatonin has recently been reported to ameliorate the harmful effects of I/R in both type 1 and type 2 diabetes. 127, 187 In their first article, using high-fat-fed streptozotocin-induced type 2 diabetic rats as well as high-fat/high-glucose-cultured H9c2 cells, Yu et al 149 focused on the involvement of Sirt1, employing sirtinol, an inhibitor of Sirt1 signalling. Rats were pretreated with melatonin (20 mg/kg/d) for a week before experimentation. In the in vivo model of I/R, melatonin upregulated Sirt1 expression, reduced oxidative damage and suppressed PERK/eIF2alpha/ATF4 signalling, effects which could be attenuated by sirtinol. Both models indicated that a reduction in Sirt1 signalling in type 2 diabetes aggravated I/R injury, effects which could be attenuated by melatonin. In a further study on streptozotocin-induced type 1 diabetic animals, 127 these workers reported that melatonin (10 mg/kg, administered orally for 5 days and an intraperitoneal injection of melatonin 10 minutes before experimentation) also reduced I/R injury in these animals using an in vivo model of coronary artery ligation, as reflected by enhanced mitochondrial SOD activity, ATP production and expression of mitochondrial complexes II, III and IV. These changes were associated with activated AMPK-PGC1alpha-Sirt3 signalling and increased NRF1 and mitochondrial transcription factor A (TFAM) expression. Interestingly, these effects could be abolished by compound C, a specific AMPK inhibitor, again indicating the significance of AMPK signalling in melatonin actions. It is well-established that AMPK is an intracellular serine/threonine protein kinase that functions as a fuel sensor in the heart. 188 As stated above, AMPK-activated PGC1alpha plays a major role in the regulation of mitochondrial biogenesis and oxidative stress, with Sirt3 as downstream target. Furthermore, the in vitro and in vivo data of Yu et al 127 showed that melatonin significantly enhanced Sirt3 signalling and suppressed oxidative stress in diabetic cardiomyocytes and it was concluded that the AMPK-PGC1alpha-Sirt3 signalling pathway plays an essential role in the melatonininduced attenuation of I/R injury in type 1 diabetes. Further studies using Sirt3-deficient animals are required to confirm the role of the AMPK-PGC1alpha-Sirt3 pathway in this scenario. It would also be interesting to evaluate the role of Sirt1 in this particular experimental setting. Similar beneficial effects of melatonin administration to type 1 diabetic rats were reported by Amin et al. 189 For example, melatonin treatment for 21 days after induction of streptozotocin-induced type 1 diabetes ameliorated the levels of hyperglycaemia, insulin, lipids and HOMA-IR, as well as decreasing the number of apoptotic cells in the heart compared to diabetic rats. Oxidative stress during diabetic pregnancy has been widely accepted as a culprit for embryopathy 190 and increased risk of postnatal diseases in the diabetic mother's offspring. 191 Melatonin is able to cross the placenta and has no obvious toxic effects on embryo development. 192 Gao et al 193 investigated whether diabetic mother offspring are more susceptible to I/R injury in adulthood compared to nondiabetic controls. Using the offspring of diabetic rat mothers, it was shown that they exhibited augmented infarct size, cardiac dysfunction and myocardial apoptosis, compared to controls. This was found to be attributable to blunted cardiac insulin receptor substrate (IRS-1/PKB) signalling. Melatonin treatment (10 mg/kg/d) of diabetic mothers resulted in a significant improvement in the tolerance to I/R injury of their offspring via restoring IRS-1/PKB signalling. These results suggested that maternal diabetes predisposes their offspring to augmented I/R injury in adulthood, a phenomenon which could be prevented by melatonin treatment during pregnancy. The exact mechanism whereby this occurs still remains to be determined.
| OTHER PATHWAYS
The present review focussed on melatonin signalling in the heart, particularly with regard to cardioprotection during I/R. Recent studies also suggested the possibility that the melatonin pathways could intersect with the Hippo signalling pathways at different places in certain malignancies. 194 Although interesting and thought-provoking, this falls outside the scope of this review.
| MELATONIN FOR CARDIOPROTECTION IN PATIENTS
As demonstrated above, melatonin has potent and reproducible cardioprotective effects in experimental animals. This has been shown repeatedly by a large number of researchers, using different models, protocols and melatonin concentrations. Thus, the time has arrived for large-scale evaluation of the therapeutic effects of melatonin in patients with acute coronary heart disease. However, translation of novel cardioprotective therapies observed in experimental animals to the human has proven to be very difficult (for reviews see refs 195,196) . Unfortunately, a large number of therapies which were highly effective in the laboratory using experimental animals have yielded very disappointing results when applied in the clinical setting. 195 In addition, attempts to reduce myocardial infarction by applying these therapies in patients with ST elevation myocardial infarction (STEMI) also failed to achieve their goal. One of the problems in evaluating new therapeutic modalities is the fact that the clinical outcomes of patients presenting with STEMI continue to improve, making it very difficult to demonstrate a further reduction in infarct size and improvement in clinical outcomes. 196 Despite these negative aspects, the positive results obtained with melatonin in experimental animals prompted researchers to evaluate the effects of melatonin in humans. A recent article reported a prospective association between lower nocturnal melatonin secretion and increased incidence of myocardial infarction 197 while low melatonin levels have also been reported in patients with coronary artery disease. 198 An independent relationship between low nocturnal melatonin serum levels and oxidized low-density lipoprotein, which plays a pivotal role in the development of atherosclerosis, has been reported in patients with acute myocardial infarction. 199 A later study from the same group also reported that serum melatonin levels were an independent predictor of LV remodelling during the chronic phase postmyocardial infarction. 200 However, coincidence does not necessarily indicate causality.
| LOCHNER Et aL.
Melatonin was able to reduce blood pressure, vascular reactivity, the pulsatile index in the carotid artery and circulatory catecholamines in healthy participants [201] [202] [203] as well as to decrease blood pressure in patients with hypertension. 204, 205 Two recent randomized placebo-controlled trials examined the cardioprotective effects of melatonin during major vascular surgery 206 and coronary artery bypass surgery. 175 Melatonin administration in the perioperative period (10 mg orally for 3 nights after surgery) reduced cardiac morbidity as well as occurrence of myocardial infarction after abdominal aortic aneurism repair. 206 Dwaich et al 175 also reported favourable outcomes: melatonin administration (10 or 20 mg capsules) for 5 days prior to coronary artery bypass surgery significantly improved the ejection fraction, and reduced plasma cardiac troponin-I, interleukin-1beta, iNOS and caspase 3 in a dose-dependent manner. Currently, there are two clinical trials (NCT00640094 and NCT 01172171) underway to test the efficacy of melatonin in patients with acute coronary heart disease. The possibility of using melatonin as therapy in these patients has been the major interest of the group of DominguezRodriguez. 12, [207] [208] [209] The safety and efficacy of melatonin as an antioxidant and the role of free radicals in reperfusion injury in STEMI patients have been the basis and rationale of the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction with Angioplasty) trial, a prospective, unicentre, randomized, double-blind, placebo-controlled study, the study design and rationale of which were first published in 2007. 207 In this study, 146 STEMI patients were randomized to melatonin (intravenous and intracoronary) or placebo during primary percutaneous coronary intervention (PPCI), the primary endpoint being infarct size. The results showed that in this nonrestricted STEMI population, melatonin was not associated with a reduction in infarct size and had an unfavourable effect on the ventricular volumes and LVEF. 208 These results led to the conclusion that, based on the European Society of Cardiology Working Group Position paper, the clinical evidence did not support melatonin as a promising therapy for reducing infarct size in reperfused STEMI patients. 210 However, post hoc analysis of the data was performed to determine whether the effect of melatonin was influenced by the time of administration. Randomized patients were divided into tertiles according to symptoms onset and balloon time: first tertile being 136 ± 23 minutes, second tertile 196 ± 19 minutes, third tertile 249 ± 42 minutes. The data showed that the effect of melatonin was determined by the timing of reperfusion: melatonin administered <2.5 hours after symptom onset could reduce infarct size by ~40%, while in the third tertile, the infarct size was smaller in the placebo-treated subjects. 211 Thus, it seems as if the timing of melatonin administration is critical for the achievement of cardioprotection.
As far as we are aware, no study has been undertaken so far to determine the optimal dose of melatonin required for cardioprotection in humans. In the MARIA trial, the patients received 51.7 micromoles melatonin given for a period of 60 minutes starting immediately before primary percutaneous coronary intervention (PPCI) and a bolus of 8.6 micromoles intracoronary melatonin given through the guiding catheter within the first 60 seconds after restoring blood flow to the infarct-related artery. 211 The rather disappointing outcomes of the MARIA trial could also be due to a too low dosage of melatonin. In this regard, Dominguez-Rodriguez and his co-workers are planning to conduct a new randomized clinical trial which aims to determine the effects of melatonin on cardiac death and heart failure hospitalization (EARLY MARIA trial). This will be an international, prospective, multicentre, randomized, double-blinded placebo-controlled trial. 12 However, it is clear that the optimal dosage of melatonin needs to be determined before final conclusions can be drawn. In addition, the best mode of administration (oral, intravenous intracoronary or combined) of melatonin is still to be validated.
In view of the fact that cardiovascular diseases are still the leading cause of death worldwide, demonstration of the reversal of the harmful effects of ischaemia/reperfusion injury by an inexpensive nontoxic medication such as melatonin could be of enormous clinical importance. The majority of clinical trials on the therapeutic usefulness of melatonin in different fields showed very low toxicity of the hormone over a wide range of doses. 212 Melatonin is readily available in pharmacologically pure form and relatively inexpensive which makes it an ideal candidate drug for use in poor populations.
| CONCLUSIONS AND LIMITATIONS
The multitude of experimental studies referred to in this review leaves little doubt that melatonin is indeed a cardioprotective agent with great potential. Although disappointing up till now, indications are that melatonin will also be effective clinically, once the problems regarding dosage, mode and timing of administration have been sorted out. Our knowledge has increased substantially regarding intracellular events following the binding of melatonin to one of its putative cell membrane receptors. Much of this knowledge emanated from studies on the effects of melatonin on intracellular signalling during myocardial I/R injury, as well as in other pathophysiological conditions such as diabetes. The multitude of signalling events following melatonin receptor stimulation with a single ligand (melatonin) and their interactions with one another remain intriguing. Also the possible interactions of the melatonin receptor with other membrane receptors need to be further evaluated. Interestingly, there appear to be similarities in the response of the cardiomyocyte to I/R injury when compared to those of CMEC.
It was attempted to summarize our current knowledge regarding melatonin signalling events in Figures 1-3 . However, due to the many caveats in our knowledge regarding the downstream events, it was impossible in many instances to indicate the exact sequence of these intermediates. It does appear that activation of a few kinases could play a pivotal role in melatonin signalling in the heart, namely PKC, PKB and AMPK. Unpublished data from our own laboratory showed that both PKB and ERK blockade, using A6730 (2.5 μmol/L) and PD098059 (10 μmol/L), respectively, abolished melatonin's cardioprotective actions in the perfused working heart model. It also became clear that phosphorylation of GSK3beta and thus its inactivation is a common downstream event in most of the possible depicted pathways. As far as we know, the significance of this kinase per se in melatonin actions has not yet been investigated. In fact, the inactivation of GSK3beta after melatonin treatment has been reported in one study only. 83 The possibility that this kinase and its effects on the mitochondrial permeability transition pore represent a final common process in melatonin-induced cell survival still needs to be verified. The recent demonstration of high levels of melatonin in brain mitochondria and the possibility of melatonin synthesis in these organelles responsible for the generation of free radicals, especially in pathophysiological conditions such as myocardial I/R, is intriguing and requires further investigation.
It is recognized that, in order to understand the cardioprotective effects of a particular intervention, knowledge of the molecular mechanisms of myocardial I/R and the changes incurred by the intervention are required. A recent position paper from the European Society of Cardiology Working Group on Cellular Biology of the Heart advocated a combination of epigenetic, transcriptomic, proteomic and metabolomic approaches in the search of therapeutic targets. 213 Using such an approach, Varga et al 214 recently described the microRNAs associated with the early phase of I/R injury in rat hearts as well as those in cardioprotection induced by ischaemic pre-and postconditioning and identified noncoding RNA molecules that may have cardioprotective effects. A combination of these omics techniques in hearts treated with melatonin may indeed be helpful in the identification of the effector(s) of protection. As far as we are aware, no such studies have been carried out on hearts treated with melatonin. However, a search of the literature revealed that melatonin significantly affected the expression of miRNAs in a variety of tissues, for example the liver, 215 cancer cells 216 and hair follicles 217 to name but a few.
Evaluation of the effects of melatonin treatment using such an approach may indeed open up new possibilities in the search for the final common effector of melatonin-induced cardioprotection.
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